

AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition comprising a compound comprising the tetrapeptide motif D/E-D/E-G/K-W, and a pharmaceutically acceptable carrier.
2. (Original) The pharmaceutical composition according to claim 1, wherein the tetrapeptide motif is DDGW.
3. (Original) Use of a compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the manufacture of a pharmaceutical composition for the treatment of conditions dependent on leukocyte migration.
4. (Original) Use according to claim 3 wherein the condition dependent on leukocyte migration is leukaemia.
5. (Original) Use according to claim 3 for the manufacture of a pharmaceutical composition for inhibiting the adhesion of progelatinases to β_2 -integrins.
6. (Original) Use of the compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the manufacture of a pharmaceutical composition for prophylaxis and treatment of conditions dependent on neutrophil migration.

7. (Original) Use according to claim 6 for the manufacture of a pharmaceutical composition for prophylaxis and treatment of inflammatory conditions.
8. (Currently Amended) Use according to ~~any one of claims 3 to 7~~ claim 3, wherein the tetrapeptide motif is DDGW.
9. (Original) A method for therapeutic or prophylactic treatment of conditions dependent on leukocyte migration, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting leukocyte migration.
10. (Original) A method for therapeutic or prophylactic treatment of conditions dependent on neutrophil migration, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting neutrophil migration.
11. (Original) A method for therapeutic or prophylactic treatment of leukaemia, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting leukaemia cell migration.
12. (Original) A method for therapeutic or prophylactic treatment of inflammatory conditions, comprising administering to a mammal in need of such treatment a compound comprising the

tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting neutrophil migration.

13. (Currently Amended) The method according to any one of claims 9 to 12 claim 9, wherein the tetrapeptide motif is DDGW.